NASDAQ:RAIN

Rain Oncology (RAIN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.21
$1.21
50-Day Range
$1.20
$1.24
52-Week Range
$0.82
$11.32
Volume
N/A
Average Volume
550,818 shs
Market Capitalization
$44.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RAIN stock logo

About Rain Oncology Stock (NASDAQ:RAIN)

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

RAIN Stock News Headlines

Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
OJ Simpson dead of cancer at 76
See More Headlines
Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RAIN
Fax
N/A
Employees
63
Year Founded
N/A

Profitability

Net Income
$-75,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.11 per share

Miscellaneous

Free Float
30,047,000
Market Cap
$44.02 million
Optionable
Optionable
Beta
0.27
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Avanish Vellanki M.B.A. (Age 49)
    Co-Founder, CEO & Chairman
    Comp: $959.75k
  • Dr. Robert C. Doebele M.D. (Age 53)
    Ph.D., Co-Founder, Chairman of Scientific Advisory Board, President & CSO and Chief Medical Officer
    Comp: $700.56k
  • Ms. Josephine Bruce (Age 45)
    Principal Financial & Accounting officer
  • Ms. Theresa O'Connell M.S.
    Director of Corporate Development & Operations
  • Mr. Erik Atkisson (Age 52)
    General Counsel & Chief Compliance Officer
  • Ms. Charmi Turner
    Vice President of People & Culture
  • Ms. Vijaya Tirunagaru Ph.D.
    Senior VP & Head of Research
  • Dr. Nora Ku M.D.
    MD & VP of Clinical Development

RAIN Stock Analysis - Frequently Asked Questions

Should I buy or sell Rain Oncology stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings
or view top-rated stocks.

How were Rain Oncology's earnings last quarter?

Rain Oncology Inc. (NASDAQ:RAIN) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.06.

When did Rain Oncology IPO?

Rain Oncology (RAIN) raised $126 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO.

This page (NASDAQ:RAIN) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners